JP2005500357A5 - - Google Patents

Download PDF

Info

Publication number
JP2005500357A5
JP2005500357A5 JP2003517072A JP2003517072A JP2005500357A5 JP 2005500357 A5 JP2005500357 A5 JP 2005500357A5 JP 2003517072 A JP2003517072 A JP 2003517072A JP 2003517072 A JP2003517072 A JP 2003517072A JP 2005500357 A5 JP2005500357 A5 JP 2005500357A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
glucosyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003517072A
Other languages
English (en)
Japanese (ja)
Other versions
JP4679055B2 (ja
JP2005500357A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/023553 external-priority patent/WO2003011881A2/en
Publication of JP2005500357A publication Critical patent/JP2005500357A/ja
Publication of JP2005500357A5 publication Critical patent/JP2005500357A5/ja
Application granted granted Critical
Publication of JP4679055B2 publication Critical patent/JP4679055B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003517072A 2001-07-27 2002-07-24 ヒドロモルホン、ジヒドロモルフィンおよびジヒドロイソモルフィンの糖誘導体、これらの組成物および痛みを治療あるいは予防するための使用 Expired - Fee Related JP4679055B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30784501P 2001-07-27 2001-07-27
PCT/US2002/023553 WO2003011881A2 (en) 2001-07-27 2002-07-24 Sugar derivatives of hydromorphone, dihydromorphine and dihydroisomorphine, compositions thereof and uses for treating or preventing pain

Publications (3)

Publication Number Publication Date
JP2005500357A JP2005500357A (ja) 2005-01-06
JP2005500357A5 true JP2005500357A5 (enExample) 2006-01-05
JP4679055B2 JP4679055B2 (ja) 2011-04-27

Family

ID=23191416

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003517072A Expired - Fee Related JP4679055B2 (ja) 2001-07-27 2002-07-24 ヒドロモルホン、ジヒドロモルフィンおよびジヒドロイソモルフィンの糖誘導体、これらの組成物および痛みを治療あるいは予防するための使用

Country Status (14)

Country Link
US (1) US6740641B2 (enExample)
EP (1) EP1412368B1 (enExample)
JP (1) JP4679055B2 (enExample)
AT (1) ATE371665T1 (enExample)
AU (1) AU2002329634B2 (enExample)
CA (1) CA2455774C (enExample)
CY (1) CY1107813T1 (enExample)
DE (1) DE60222137T2 (enExample)
DK (1) DK1412368T3 (enExample)
ES (1) ES2292806T3 (enExample)
IL (2) IL160085A0 (enExample)
MX (1) MXPA04000825A (enExample)
PT (1) PT1412368E (enExample)
WO (1) WO2003011881A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060708B2 (en) * 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7338939B2 (en) * 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US20070066537A1 (en) * 2002-02-22 2007-03-22 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
IL163668A0 (en) * 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Use of peptide-drug conjugation to reduce inter-subject variability ofdrug serum levels
US7700561B2 (en) * 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
IL163667A0 (en) * 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Novel sustained release pharmaceutical compounds to preventabuse of controlled substances
US7659253B2 (en) 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
GB0218811D0 (en) * 2002-08-14 2002-09-18 Cenes Ltd Salts of morphine-6-glucuronide
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
BRPI0410792B8 (pt) 2003-05-29 2021-05-25 New River Pharmaceuticals Inc compostos de anfetamina resistentes à dependencia
NZ546226A (en) * 2003-09-30 2009-03-31 Shire Llc Oxycodone conjugates for prevention of overdose or abuse
KR101453107B1 (ko) * 2006-04-21 2014-10-27 디에스엠 아이피 어셋츠 비.브이. 오피오이드 수용체 길항제의 용도
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
FR2939436B1 (fr) * 2008-12-10 2010-12-17 Sanofi Aventis Synthese de morphine-6-glucuronide ou de l'un de ses derives
US8716350B2 (en) * 2010-03-30 2014-05-06 Algynomics Inc. Compositions and methods for the treatment of somatosensory disorders
WO2011126910A2 (en) 2010-03-30 2011-10-13 Algynomics Inc. Compositions and methods for the treatment of somatosensory disorders
JP5977240B2 (ja) 2010-09-21 2016-08-24 パーデュー、ファーマ、リミテッド、パートナーシップ ブプレノルフィン類似体
CN104136031B (zh) 2011-10-26 2016-05-04 凯姆制药公司 氢吗啡酮的苯甲酸缀合物、苯甲酸衍生物缀合物和杂芳基羧酸缀合物、其前药、制备和使用方法
TW201431842A (zh) 2012-11-09 2014-08-16 Purdue Pharma Lp 苯並嗎啡烷類似物及其應用
JP6317755B2 (ja) 2012-12-07 2018-04-25 パーデュー、ファーマ、リミテッド、パートナーシップ オピオイド受容体モジュレーターとしてのブプレノルフィン類似体
JP6100917B2 (ja) 2012-12-14 2017-03-22 パーデュー、ファーマ、リミテッド、パートナーシップ ピリドンモルフィナン類似体およびオピオイド受容体に対する生物活性
TW201434837A (zh) 2012-12-14 2014-09-16 Purdue Pharma Lp 螺環嗎啡喃及其用途
JP6182620B2 (ja) 2013-01-31 2017-08-16 パーデュー、ファーマ、リミテッド、パートナーシップ ベンゾモルファン類似体およびその使用
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
HU231191B1 (hu) 2013-04-15 2021-08-30 Szegedi Tudományegyetem Izotóp tartalmú morfin molekulák
EP3087078B1 (en) 2013-12-26 2019-05-15 Purdue Pharma LP 7-beta-alkyl analogs of orvinols
CN106414408A (zh) 2013-12-26 2017-02-15 普渡制药公司 缩合环吗啡喃和其用途
WO2015097547A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. 10-substituted morphinan hydantoins
EP3087079B1 (en) 2013-12-26 2019-04-03 Purdue Pharma LP Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
WO2015097546A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Propellane-based compounds and their use as opioid receptor modulators
WO2015099863A1 (en) 2013-12-27 2015-07-02 Purdue Pharma L.P. 6-substituted and 7-substituted morphinan analogs and the use thereof
WO2015183780A1 (en) 2014-05-27 2015-12-03 Purdue Pharma L.P. Spirocyclic morphinans and use thereof
JP6360915B2 (ja) 2014-06-13 2018-07-18 パーデュー、ファーマ、リミテッド、パートナーシップ アザモルフィナン誘導体及びその使用
RU2683274C2 (ru) 2014-12-02 2019-03-27 Кемфарм, Инк. Бензойная кислота, производные бензойной кислоты и конъюгаты гетероарилкарбоновой кислоты и оксиморфона, их пролекарства, способы получения и применение
MA41125A (fr) 2014-12-05 2017-10-10 Purdue Pharma Lp Dérivés de 6.7-cyclomorphinane et leur utilisation
ITUB20154996A1 (it) 2015-10-27 2017-04-27 Nobili S P A Attrezzatura per l?erogazione di un liquido di trattamento ad una rispettiva coltura o piantagione agricola.
RS66574B1 (sr) 2016-07-29 2025-03-31 Janssen Pharmaceutica Nv Niraparib za upotrebu u postupku lečenja raka prostate
WO2018125716A1 (en) 2017-01-02 2018-07-05 Purdue Pharma L.P. Morphinan derivatives and use thereof
WO2020012245A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Thienothiophene-naltrexone prodrugs for long-acting injectable compositions
US10799496B2 (en) 2018-07-13 2020-10-13 Alkermes Pharma Ireland Limited Naphthylenyl compounds for long-acting injectable compositions and related methods
US10975099B2 (en) 2018-11-05 2021-04-13 Alkermes Pharma Ireland Limited Thiophene compounds for long-acting injectable compositions and related methods
WO2024042226A2 (en) * 2022-08-25 2024-02-29 Biosynth Gmbh Procedure for production of opioid-antagonist-releasing compounds and their use as a medicine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0324212B1 (en) 1988-01-12 1993-08-04 Baker Norton Pharmaceuticals, Inc. Glucuronic acid derivatives of opioid antagonists
FR2680786B1 (fr) * 1991-09-04 1995-03-10 Irepa Procede de synthese de glucuronides d'epoxy-4,5 morphinanes.
WO1997021416A2 (es) 1995-11-29 1997-06-19 Rolabo Sl Glicoconjugados de substancias opiaceas
GB9711118D0 (en) 1997-05-29 1997-07-23 Rolabo Sl Compound

Similar Documents

Publication Publication Date Title
JP2005500357A5 (enExample)
JP2003503454A5 (enExample)
JP2006504723A5 (enExample)
PT1326613E (pt) Utilizacao de derivados de imidazo[1,2-a]piridin-,imidazo[1,2-a]pirimidin- e imidazo[1,2-a]pirazin-3-il-amina substituidos para a fabricacao de medicamentos para inibicao de nos
DE60222137D1 (de) Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen
GB0022438D0 (en) Organic Compounds
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
CY1111615T1 (el) Αρυλβινυλαζακυκλοαλκανια και μεθοδοι παρασκευης και χρησεως τους.
JP2006514116A5 (enExample)
NZ605469A (en) Nalbuphine-based formulations and uses thereof
JP2003526626A5 (enExample)
TW200624431A (en) Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
JP2005507892A5 (enExample)
RU2003118411A (ru) Кристаллические производные 1-метилкарбапенема
ES2139673T3 (es) Utilizacion de norastemizol para el tratamiento de rinitis alergica.
JP2008513510A5 (enExample)
WO2007038112A3 (en) Combination of rosiglitazone and donepezil for improvement of cognitive function
MY133527A (en) Isoquinoline derivatives
DE602004016376D1 (de) Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
JP2010500284A5 (enExample)
JP2003514025A5 (enExample)
RU2006113366A (ru) Терапевтическое лечение
JP2002537232A5 (enExample)
JP2008513426A5 (enExample)
JP2005513036A5 (enExample)